Skip To Main Content
Dimopoulos MA on Muck Rack

Dimopoulos MA

As seen in: Wiley Online Library, Oncology Central
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Dimopoulos MA’s profile

Articles by Dimopoulos MA

A plain language summary of the PERSEUS study: daratumumab + VRd treatment options for newly diagnosed multiple myeloma

|
By Dimopoulos MA, Jade Parker
| Oncology Central Verified
Our partner journal Future Oncology recently published a plain language summary of publication describing the first analysis of the PERSEUS study. The PERSEUS trial is investigating the addition of daratumumab to bortezomib, lenalidomide and dexamethasone (VRd) for adults with multiple myeloma that had never been treated before. View the journal article here What is this summary about?
Open in Who Shared Issue with article?
|
By et al. Daratumumab, DARA Maintenance, Dimopoulos MA
| chase.com
DARZALEX (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma 1:05 PM EDT 9/27/2024 - Comtex RIO DE JANEIRO, Sept.
Open in Who Shared View Duplicates (69) Issue with article?

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

|
By Dimopoulos MA, D'Sa S, Lee HP, Owen RG
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (586) Issue with article?

Reply to S. Sarosiek et al

|
By Dimopoulos MA
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (666) Issue with article?

Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study - PubMed

|
By Ntanasis-Stathopoulos I, Dimopoulos MA, Kyrtsonis MC
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (634) Issue with article?

Surgical Treatment of Solitary Metachronous Adrenal Metastasis from Urothelial Carcinoma of the Urinary Bladder

|
By Dimopoulos MA, Alexandraki KI
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (341) Issue with article?

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network - PubMed

|
By Mateos MV, Dimopoulos MA, San-Miguel J, Rodriguez-Otero P
| ncbi.nlm.nih.gov
Skip to main page content Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software Review doi: 10.1016/S1470-2045(23)00159-6.
Open in Who Shared Issue with article?

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature

|
By Ntanasis-Stathopoulos I, Dimopoulos MA
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (594) Issue with article?

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

|
By Dimopoulos MA, Min CK, Risse ML
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (599) Issue with article?

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

|
By Ntanasis-Stathopoulos I, San-Miguel J, Dimopoulos MA, Vangsted AJ
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (552) Issue with article?

Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

|
By Dimopoulos MA, Harrison SJ, Weisel KC, Badros AZ
| ncbi.nlm.nih.gov
Review doi: 10.1016/S1470-2045(23)00223-1. Affiliations Affiliations 1 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece. 2 Amyloidosis Research and Treatment Center, IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy. 3 Department of Nephrology, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France.
Open in Who Shared Issue with article?

Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies - PubMed

|
By Richardson PG, Dimopoulos MA, Schjesvold FH, Bakker NA
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (265) Issue with article?

Evolution of diagnostic workup and treatment for multiple myeloma 2013‐2019

|
By Fredrik Schjesvold, Mary JY, Dimopoulos MA, Kumar SK
| pericles.pericles-prod.literatumonline.com
Abstract Objective To evaluate changes in diagnostic and therapeutic approach in multiple myeloma among Norwegian hematologists in the current decade. Methods This nationwide study in Norway is based on results of surveys conducted among professionally active hematologists from 2013 to 2019. Every year, respondents participating in the survey suggested treatment regimens used in typical clinical situations in patients with multiple myeloma, as well as diagnostic routines.
Open in Who Shared Issue with article?

Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

|
By S. Vincent Rajkumar, Rajkumar SV, Dimopoulos MA, Kyle RA
| Wiley Online Library Verified
Abstract Multiple myeloma accounts for approximately 10% of hematologic malignancies.
Open in Who Shared Issue with article?

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis ... - PubMed - NCBI

|
By Dimopoulos MA
| ncbi.nlm.nih.gov
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow-up and include the effect on minimal residual disease and in clinically relevant subgroups.
Open in Who Shared Issue with article?

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.

|
By Dimopoulos MA
| ncbi.nlm.nih.gov
Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is the recommended method for the assessment of renal function in patients with MM with stabilized serum creatinine. In acute renal injury, the RIFLE (risk, injury, failure, loss and end-stage kidney disease) and Acute Renal Injury Network criteria seem to be appropriate to define the severity of renal impairment.
Open in Who Shared Issue with article?

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised,... - PubMed - NCBI

|
By Dimopoulos MA
| ncbi.nlm.nih.gov
The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis. The aim of this second interim analysis was to compare overall survival between the two treatment groups.
Open in Who Shared Issue with article?

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

|
By Dimopoulos MA
| ncbi.nlm.nih.gov
The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI). Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group.
Open in Who Shared Issue with article?

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting

|
By Dimopoulos MA
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (582) Issue with article?
Show More